Ablynx NV logo

ABLX - Ablynx NV Share Price

$52.87 0.1  0.2%

Last Trade - 12/06/18

Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £48.3m
Position in Universe th / 6718
Unlock ABLX Revenue
Relative Strength (%)
1m -6.17%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
26.7 35.9 49.3 77.5 85.2 55.5 94.0 176.5 +15.7%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2017, AblynxNV revenues decreased 35% to EUR55.5M. Net loss increasedfrom EUR1.1M to EUR108.5M. Revenues reflect Grants decreasefrom EUR414K to -EUR31K. Higher net loss reflects ChangesFair Value Derivative decrease from EUR34.3M (income) toEUR0K, Other General and Administration Expense increase of61% to EUR12.4M (expense), Employee benefits expenses inR&D increase of 14% to EUR30.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ABLX Revenue Unlock ABLX Revenue

Net Income

ABLX Net Income Unlock ABLX Revenue

Normalised EPS

ABLX Normalised EPS Unlock ABLX Revenue

PE Ratio Range

ABLX PE Ratio Range Unlock ABLX Revenue

Dividend Yield Range

ABLX Dividend Yield Range Unlock ABLX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ABLX EPS Forecasts Unlock ABLX Revenue
Profile Summary

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck Serono and Novartis.

Last Annual December 31st, 2017
Last Interim December 31st, 2017
Incorporated July 13, 2001
Public Since March 9, 2010
No. of Shareholders: n/a
No. of Employees: 438
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange NASDAQ Global Select Market (Dual Listing)
Shares in Issue 78,001,392
Free Float (0.0%)
Eligible for
ABLX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ABLX
Upcoming Events for ABLX
Frequently Asked Questions for Ablynx NV
What is the Ablynx NV share price?

As of 12/06/18, shares in Ablynx NV are trading at $52.87, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Ablynx NV share price performed this year?

Shares in Ablynx NV are currently trading at $52.87 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Ablynx NV price has moved by % over the past year.

What are the analyst and broker recommendations for Ablynx NV?

There are no analysts currently covering Ablynx NV.

When will Ablynx NV next release its financial results?

Ablynx NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2018-12-31
What is the Ablynx NV dividend yield?

Ablynx NV does not currently pay a dividend.

Does Ablynx NV pay a dividend?

Ablynx NV does not currently pay a dividend.

When does Ablynx NV next pay dividends?

Ablynx NV does not currently pay a dividend.

How do I buy Ablynx NV shares?

To buy shares in Ablynx NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Ablynx NV?

Shares in Ablynx NV are currently trading at $52.87, giving the company a market capitalisation of £n/a.

Where are Ablynx NV shares listed? Where are Ablynx NV shares listed?

Here are the trading details for Ablynx NV:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ABLX
What kind of share is Ablynx NV?

We were not able to load our ranking data for Ablynx NV

Is there a Ablynx NV share price forecast 2021?

We were not able to load any forecast data for Ablynx NV.

How can I tell whether the Ablynx NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ablynx NV. Over the past six months, the relative strength of its shares against the market has been 96.11%. At the current price of $52.87, shares in Ablynx NV are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Ablynx NV PE Ratio?

We were not able to find PE ratio data for Ablynx NV.

Who are the key directors of Ablynx NV?

We were unable to find the directors for Ablynx NV.

Who are the major shareholders of Ablynx NV?

Here are the top five shareholders of Ablynx NV based on the size of their shareholding:

Similar to ABLX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.